Test Directory

Clear All
Test Code
1789
Test Name
Craniodiaphyseal Dysplasia, Autosomal Dominant
CPT Codes
81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.
Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours
Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Alternate Names
CDD
Description

Craniodiaphyseal dysplasia (CDD; MIM 122860) is a rare sclerosing bone dysplasia characterized by severe hyperostosis and sclerosis, particularly of the skull and facial bones.  The bone overgrowth is so profound it results in facial distortion, respiratory obstruction due to choanal stenosis, destruction of the sinuses, hearing loss, optic nerve atrophy, increased intracranial pressure, and stenosis of the cranial foramina.  The long bones show an extreme hyperostosis and sclerosis of the diaphyses and defective modeling of the metaphyses.  Symptoms of CDD are usually present in infancy and the disorder is often lethal in childhood.  CDD is caused by mutations in the SOST gene, which encodes sclerostin, a protein that decreases osteoblast activity and inhibits bone formation.  All currently reported CDD mutations occur at a single amino acid, Val21, within the secretion signal region of SOST and appear to prevent secretion of sclerostin.  Mutations in SOST also cause hyperostosis corticalis generalisata (Van Buchem disease; MIM 239100) and sclerosteosis (MIM 269500), two autosomal recessive sclerosing bone disorders with milder clinical features.
Testing Schedule
Monday-Friday
Genes
SOST
MIM
122860
Disease Group
Skeletal Disorders
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.